Baird raised the firm’s price target on Medpace (MEDP) to $362 from $354 and keeps a Neutral rating on the shares. The firm preiovewed its Q4 results and guidance.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.